Technology | Wearables | March 05, 2019

VivaLNK Launches IoT-Enabled Medical Wearable Sensor Platform

Platform captures and aggregates vitals and biometrics from wearable devices into a data cloud

VivaLNK Launches IoT-Enabled Medical Wearable Sensor Platform

March 5, 2019 — Connected healthcare solutions provider VivaLNK announced its internet of things (IoT)-enabled medical wearable Sensor Platform, complete with a range of sensors, edge computing technologies and an internet of health things (IoHT) data cloud. This platform captures human vitals and biometrics, and delivers data from the patient to edge computing devices, as well as to the cloud, for application integration and analysis.

Available through the VivaLNK Developer Program, the Sensor Platform enables IoHT solution partners to easily capture streams of patient data such as heart and respiratory rates, temperature, electrocardiogram (ECG) rhythms, activity and more. Partners such as Vitalic Medical, a digital health company focusing on early detection of patient health deterioration and potential falls, is developing a bedside monitoring solution using the platform.

IoHT has the potential to significantly change healthcare for the better, and the key starts with data, according to VivaLNK. Much of the machine learning and intelligence will come from user-generated data that currently does not exist or is not easily accessible. This is where wearable devices collecting medical-grade data that can easily connect to networked applications becomes crucial.

VivaLNK showcased its new platform at the 2019 Healthcare Information and Management Systems Society (HIMSS) conference, Feb. 11-15 in Orlando, Fla.

For more information: www.vivalnk.com

Related Content

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Overlay Init